Skip to content

Behzad Aghazadeh, Director at Scribe Therapeutics, bought SCTX on Jul 24, 2026

Data as of Oct 16

▲ BUY$1.1M50,000 shares at $22.31Behzad Aghazadeh DirectorSCTX Scribe Therapeutics, Inc.
Watch SCTX
Traded
Jul 24, 2026
Disclosed
Jul 28, 2026
Filed
4 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Behzad Aghazadeh, Director at Scribe Therapeutics, bought SCTX on Jul 24, 2026TRADEDDISCLOSED
SCTXSimilar stocks (XLV — its sector index fund), rebased to SCTX's price on the disclosure day
SCTX since disclosure
+11.2%
Similar stocks (XLV) since disclosure
+5.6%
XLV — its sector index fund

Change in closing price from Jul 28, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▲ BUYAvoro Ventures LLC DirectorSCTX Scribe Therapeutics, Inc.$144Kdisclosed Jul 28 · filed the same day
  2. ▲ BUYBehzad Aghazadeh DirectorSCTX Scribe Therapeutics, Inc.$144Kdisclosed Jul 28 · filed the same day
  3. ▲ BUYAvoro Capital Advisors LLC DirectorSCTX Scribe Therapeutics, Inc.$144Kdisclosed Jul 28 · filed the same day
  4. ▲ BUYAvoro Ventures LLC DirectorSCTX Scribe Therapeutics, Inc.$35Mdisclosed Jul 28 · filed 4 days after the trade
  5. ▲ BUYAvoro Capital Advisors LLC DirectorSCTX Scribe Therapeutics, Inc.$35Mdisclosed Jul 28 · filed 4 days after the trade
  6. ▲ BUYBehzad Aghazadeh DirectorSCTX Scribe Therapeutics, Inc.$35Mdisclosed Jul 28 · filed 4 days after the trade
  7. ▲ BUYAvoro Ventures LLC DirectorSCTX Scribe Therapeutics, Inc.$1.1Mdisclosed Jul 28 · filed 4 days after the trade
  8. ▲ BUYAvoro Capital Advisors LLC DirectorSCTX Scribe Therapeutics, Inc.$1.1Mdisclosed Jul 28 · filed 4 days after the trade

See every trade on SCTX →